Seeking Alpha

Andrew Nava's  Instablog

Andrew Nava
Send Message
Andrew Nava LLC is a healthcare focused consulting and investment firm. Prior to launching Andrew Nava LLC, I was a venture analyst, buy-side analyst, and most recently, the Director of Research at Actin Biomed, a New York-based healthcare investment firm where I was responsible for the medical,... More
My company:
Andrew Nava, LLC
  • Companies Presenting Data at ASCO 0 comments
    May 27, 2010 12:06 AM | about stocks: ABII, AEZS, ALNY, AMGN, ARIA, ARQL, ARRY, AVEO, BIIB, CELG, CLDX, CTIC, CYCC, DCTH, DNDN, EXEL, SNY, GNBT, HNAB, IMGN, IMMU, INCY, INFI, KERX, MITI, MEIP, MYRX, NKTR, OGXI, ONCY, ONTY, ONXX, OSIP, OXGN, PARD, PCYC, PPHM, PVCT, SCLN, SGEN, SNSS, SPPI, THLD, GILD, ZGEN, ZIOP
    Below is a brief list of companies presenting data at ASCO.  A complete list of upcoming milestones can be found at AndrewNava.com.  AndrewNava.com is our exclusive database covering over 290 publicly-traded biotechnology and pharmaceutical companies, more than 1000 profiles of approved and development-stage drugs, devices and diagnostics, hundreds of clinical trial results and data, product sales, and 17 different stock catalyst types.

    ABII: Abraxane NSCLC late-breaker (top-line reported 3/17/10), phase 2 pancreatic survival data expected in time for late-breaker (#4120).

    AEZS: AEZS-108 ovarian data expected (#5035)

    ALNY: Preliminary data expected from ALN-VSP phase 1 study in patients with advanced solid tumors w/ liver involvement (#3042).

    AMGN: Full Prostate SRE data expected (Study 103) – Abstract #4507.

    ARIA: Updated AP24534 phase 1 data expected (#53232), Ridaforolimus solid tumor data (#48347 and #48828).

    ARQL: Full ARQ 197 phase 2 NSCLC data expected (top-line announced in March) – Oral presentation #LBA7502, submitted as late breaker with embargo to be lifted June 5.

    ARRY: AZD6244 thyroid data expected (#5536), ARRY-520 rrMM and solid tumor data expected (#8132, #2570).

    AVEO: Tivozanib RCC data (#3103 and #4599), AV-299 (#2525).

    BIIB: Phase 3 PRIMA study of RITUXAN as latent therapy for indolent NHL (oral presentation).

    CELG: 50+ abstracts expected w/ 10+ oral presentations (CALGB and IFM Post-ASCT MM, REVLIMID in Elderly CLL, REVLIMID in DLBCL, REVLIMID and Rituxan in Follicular Lymphoma, Pomalidomide in Relapsed/Refractory MM).

    CLDX: Updated CXD-110 survival data from ACT III trial expected, Final phase 1/2 melanoma data for CDX-011, phase 1 update for CDX-1307 epithelial cancers (breast, colon, pancreatic).

    CTIC: Opaxio esophageal data expected (#4085), Brostallicin sarcoma data expected (#10037).

    CYCC: Interim Sapacitabine phase 2 MDS data expected (#6528).

    DCTH: Oral presentation expected for PHP Melphalan phase 3 study.

    DNDN: Further Provenge survival data expected (#4550, #4551, #4552).

    EXEL: Data updates expected for XL184 (#5502, #3017, #TPS188, #2006) XL147, XL765, XL228 and XL139.

    GENZ: Phase 3 Leukine data in melanoma, Leukine data in prostate cancer, Clolar data in MDS, NHL, and AML.

    GETA: Tesetaxel data expected from q21 (q3week) schedule (abstract submitted as of Feb), final melanoma data expected (phase 2 Abraxane/Temodar combo trial).

    GNBT: Data expected for AE37 (preclinical).

    HNAB: Oral presentation on full phase 2 Marqibo ALL trial.

    HRBR: Apoptone phase 1/2 prostate data expected.

    IMGN: Initial clinical data expected for IMGN388 (#3058) and BIIB015, interim data from Phase Ib/II trial using T-DM1 with pertuzumab, T-DM1 data expected (#1012 and #1016).

    IMMU: Updated Clivatuzumab tetraxetan data expected from ongoing Phase 1/2 pancreatic CA in combination with gemcitabine.

    IMUC: glioblastoma data expected (median PFS in newly diagnosed = 17.7 months vs RT/TMZ 6.9 months).

    INCY: INCB7839 breast cancer poster expected.

    INFI: IPI-504 data expected for NSCLC study (#7517).

    KERX: Phase 1 perifosine pediatric data expected (includes neuroblastoma) – Abstract #9540, phase 2 colorectal data expected (Abstract #3531).

    LPTN: Detailed phase 1 data expected for ASONEP.

    MITI: Updated phase 1 MT110 data from gastric and and lung CA (#2573).

    MSHL: Phenoxodiol prostate data expected (#4661)

    MYG: Updated MGCD265 clinical data from Trials 101 and 102 expected (#3108 and #3106), MGCD0103 follicular lymphoma (#8086).

    MYRX: Data expected for Azixa (melanoma, GBM, abstracts #8531 and #295, respectively) and MPC-3100 for solid tumors (# e13112).

    NKTR: NKTR-102 ovarian data expected at ASCO (oral presentation, #5013), NKTR-105 updated phase 1 data expected (solid tumors).

    OGXI: Final OGX-427 phase 1 data expected.

    ONCY: Phase 1/2 Reolysin SCCHN data expected

    ONTY: Phase 1 data expected for PX-866 (#3089) and PX-478 (#3076)

    ONXX: Nexavar data expected (HCC, RCC, lung, breast), Carfilzomib data expected.

    OSIP: Data expected from CALGB 30406 phase 2/3 1st-line never-smokers study.

    OXGN: Updated efficacy/safety from FALCON study (NSCLC), final phase 1 solid tumor data expected for OXi4503.

    PARD: Oral presentation at ASCO from Picoplatin Phase 3 SPEAR trial.

    PCYC: Further PCI-32765 data (3rd-5th dose cohorts), Oral Session Abstract ID 8012 titled “Btk inhibitor PCI-32765 monotherapy induces objective responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study.”

    PPHM: Three abstracts expected on bavituximab (breast combo w/ docetaxel – #1042, breast combo w/ pac/carb – #1062, and NSCLC w/ pac/carb – #7589), one abstract on Cotara (GBM) – #48393.

    PVCT: Full PV-10 phase 2 melanoma data to be presented (#8534).

    SCLN: SCV-07 mucositis late breaker submitted.

    SGEN: Data expected at ASCO from retreatment of patients with Hodgkin lymphoma and systemic ALCL (Abstract # 8062).

    SNSS: Oral presentation of final data from phase 2 voreloxin ovarian cancer (Abstract #5002), posters from two Phase 2 studies of voreloxin in AML (Abstract #6525 and #6526).

    SPPI: Belinostat PTCL data expected (#e18565), also expected is data from unknown primary (#TPS185), HCC (#2585), and MDS (#6607)

    THLD: 5 abstracts submitted (as of JPMorgan) on TH-302.

    YMI: Nimotuzumab data expected for GBM (#2056) and H&N (#5530 and #5565),

    ZGEN: Full IL-21 data expected from Phase 2a melanoma study.

    ZIOP: PICASSO Trial Abstract Selected for 2010 Best of ASCO Meeting Program (#10004).

    Abstracts can be viewed right here.

    For additional articles on ASCO, check out:

    Investopedia

    WealthDaily

    Andrew Nava LLC provides institutional and retail healthcare investors with buy-side equity research tools which focus on value-driven investing, profitable trading ideas and clinical, commercial, and regulatory catalysts. Our research is supported by consulting with KOL's, industry professionals, company management, and our database of clinical trial data and upcoming company milestones.


    Disclosure: Long KERX, CYCC, CLDX
Back To Andrew Nava's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.